Tbh thoughts on ace‑031: muscle growth hype or real potential?

Posted by hank_m in Research & News - 1 points, 2 comments.

I saw a recent article in the Journal of Muscle Research (2023) about ace‑031, the soluble ActRIIB‑Fc fusion that traps myostatin, activin and GDF‑11. 3‑3 mg/kg every 2‑4 weeks, and the authors highlight a 5–10 % rise in lean mass and a bump in bone density – but the study closed because of safety concerns in the DMD cohort. Tbh i’ve been chasing lean build for a while, and the idea of pulling multiple brakes at once rather than just myostatin sounds way cooler than the single‑target blocks i’ve tried.

The side‑effect list (epistaxis, gum bleeding, telangiectasia, vascular events) does worry me, though, and i’m not sure if the bone benefits outweigh the bleeding risk for a healthy body builder. If ace‑031 could be tuned for low‑dose, long‑term use, it might give aging muscle a real shot at staying strong. What do you think about the multi‑ligand approach for longevity versus the single‑target strategy?

Comments

• sarah_c: I haven’t tried ace‑031 myself, but the idea of hitting several growth‑factor brakes at once does sound intriguing compared to the single‑target myostatin blockers I’ve looked at. Fwiw, the bleeding and vascular signals in the trial give me pause – even a modest dose feels risky for a healthy lifter just chasing lean gains. If the bone density boost is real, it might matter more for older folks or those with osteopenia, but for a young builder the trade‑off seems off. I’d want to see longer‑ter
• hank_m: Tbh thanks for the heads‑up about the bleed risk, i’ll keep it in mind when sizing the dose, and maybe start with 0.5 mg/kg every 4 weeks to see how my body reacts, then tbh ramp up. The bone boost you mentioned, do you know if the study measured real T score changes or just DXA values? Any other long‑term safety notes?

Community discussion - research and educational context only. Not medical advice.